Literature DB >> 35109737

"I've been 95% safe": perspectives on HIV pre-exposure prophylaxis at a drug detoxification center: a qualitative study.

Eugene S G Massey1,2, Angela R Bazzi1,3, Carlos R Sian4, Christina M Gebel1, Judith A Bernstein1, Sabrina A Assoumou4,5.   

Abstract

Pre-exposure prophylaxis (PrEP) decreases human immunodeficiency virus (HIV) acquisition among persons who inject drugs (PWID); however, its uptake has been suboptimal. We explored HIV risk perceptions and PrEP interest among drug detoxification center patients in the context of the ongoing opioid overdose epidemic. We conducted in-depth interviews of patients (n = 24) and professional key informants (n = 10 physicians, case managers, nurses, and harm reduction educators), and thematic analysis of coded data. The mean age of participants (patients) was 37 years; 54% identified as male and 67% as White. Although 71% reported injecting drugs and 62% had condomless sex in the past 6 months, participants had mixed HIV risk perceptions, and some viewed PrEP as an undesirable indicator of elevated HIV risk. Nevertheless, many participants viewed drug detoxification as a first step towards embarking on a "healthier lifestyle," with some narratives identifying opportunities for delivering PrEP information and services in this setting. Opportunities exist to expand PrEP at drug detoxification centers, but initiatives are needed to educate patients and staff on indications and benefits of this prevention tool. Interventions are also needed to determine the best strategies for implementing PrEP adoption in this setting.

Entities:  

Keywords:  Human immunodeficiency virus; drug detoxification center; persons who inject drugs; pre-exposure prophylaxis

Year:  2022        PMID: 35109737      PMCID: PMC9343469          DOI: 10.1080/09540121.2022.2031853

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  13 in total

1.  Limited Knowledge and Mixed Interest in Pre-Exposure Prophylaxis for HIV Prevention Among People Who Inject Drugs.

Authors:  Angela R Bazzi; Dea L Biancarelli; Ellen Childs; Mari-Lynn Drainoni; Alberto Edeza; Peter Salhaney; Matthew J Mimiaga; Katie B Biello
Journal:  AIDS Patient Care STDS       Date:  2018-10-11       Impact factor: 5.078

Review 2.  Content analysis and thematic analysis: Implications for conducting a qualitative descriptive study.

Authors:  Mojtaba Vaismoradi; Hannele Turunen; Terese Bondas
Journal:  Nurs Health Sci       Date:  2013-03-11       Impact factor: 1.857

3.  Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement.

Authors:  Douglas K Owens; Karina W Davidson; Alex H Krist; Michael J Barry; Michael Cabana; Aaron B Caughey; Susan J Curry; Chyke A Doubeni; John W Epling; Martha Kubik; C Seth Landefeld; Carol M Mangione; Lori Pbert; Michael Silverstein; Melissa A Simon; Chien-Wen Tseng; John B Wong
Journal:  JAMA       Date:  2019-06-11       Impact factor: 56.272

4.  Barriers and Facilitators to PrEP Use Among People Who Inject Drugs in Rural Appalachia: A Qualitative Study.

Authors:  Sean T Allen; Allison O'Rourke; Rebecca Hamilton White; Katherine C Smith; Brian Weir; Gregory M Lucas; Susan G Sherman; Suzanne M Grieb
Journal:  AIDS Behav       Date:  2020-06

5.  Rapid Versus Laboratory-Based Testing for HIV and Hepatitis C at a Drug Detoxification Treatment Center: A Randomized Trial.

Authors:  Sabrina A Assoumou; Samantha M Paniagua; Benjamin P Linas; Jianing Wang; Jeffrey H Samet; Jonathan Hall; Laura F White; Curt G Beckwith
Journal:  J Infect Dis       Date:  2020-09-02       Impact factor: 5.226

6.  HIV Pre-Exposure Prophylaxis Prevention Awareness, Willingness, and Perceived Barriers among People Who Inject Drugs in Los Angeles and San Francisco, CA, 2016-2018.

Authors:  Suzan M Walters; Alex H Kral; Kelsey A Simpson; Lynn Wenger; Ricky N Bluthenthal
Journal:  Subst Use Misuse       Date:  2020-09-23       Impact factor: 2.164

7.  Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors.

Authors:  Lynn E Sullivan; Brent A Moore; Marek C Chawarski; Michael V Pantalon; Declan Barry; Patrick G O'Connor; Richard S Schottenfeld; David A Fiellin
Journal:  J Subst Abuse Treat       Date:  2007-10-15

8.  Patients at a drug detoxification center share perspectives on how to increase hepatitis C treatment uptake: A qualitative study.

Authors:  Sabrina A Assoumou; Carlos R Sian; Christina M Gebel; Benjamin P Linas; Jeffrey H Samet; Judith A Bernstein
Journal:  Drug Alcohol Depend       Date:  2021-01-11       Impact factor: 4.492

9.  HIV Pre-exposure Prophylaxis and Buprenorphine at a Drug Detoxification Center During the Opioid Epidemic: Opportunities and Challenges.

Authors:  Sabrina A Assoumou; Samantha M Paniagua; Priscilla Gonzalez; Jianing Wang; Curt G Beckwith; Laura F White; Jessica L Taylor; Kristen Coogan; Jeffrey H Samet; Benjamin P Linas
Journal:  AIDS Behav       Date:  2021-03-22

10.  High Prevalence of Indications for Pre-exposure Prophylaxis Among People Who Inject Drugs in Boston, Massachusetts.

Authors:  Joel J Earlywine; Angela R Bazzi; Katie B Biello; R Monina Klevens
Journal:  Am J Prev Med       Date:  2020-11-21       Impact factor: 5.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.